Department of Surgery, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
Health Sciences North Research Institute, Sudbury, Ontario, Canada.
JAMA Netw Open. 2021 Feb 1;4(2):e2036330. doi: 10.1001/jamanetworkopen.2020.36330.
Proponents of novel transanal total mesorectal excision (TME) suggest the procedure overcomes the technical and oncologic challenges of conventional approaches for treating rectal cancer. Recently, however, there has been controversy regarding the oncologic safety of the procedure.
To assess the association of transanal TME with the incidence of local recurrence (LR) of cancer and the probability of remaining free of LR during follow-up.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study used data from 8 high-volume rectal cancer academic institutions from across Canada on all consecutive patients with primary rectal cancer treated by transanal TME at the participating centers. The study was conducted between January 2014 and December 2018, and data were analyzed from April 1, 2020, to September 15, 2020.
Transanal TME.
The incidence of LR was reported as a direct measure of quality of resection. The cumulative probability of LR- and systemic recurrence (SR)-free survival at 36 months was estimated. Local recurrence and SR were defined as radiologic or endoscopic evidence of 1 or more new lesions in or outside the pelvis, respectively, documented during surveillance after the removal of the primary tumor.
Of 608 total patients included in the analysis, 423 (69.6%) were male; the median age was 63 years (interquartile range [IQR], 54-70 years). Local recurrence was identified in 22 patients (3.6%) after a median follow-up of 27 months (IQR, 18-38 months). The median time to LR was 13 months (IQR, 9-19 months). Sixteen of the 22 patients with LR (72.7%) were male, 14 (63.6%) received neoadjuvant chemoradiation, and 12 (54.5%) had American Joint Committee on Cancer stage III disease. Of those with LR, 16 (72.7%) had a negative circumferential radial margin and 20 (90.9%) had a negative distal resection margin, 2 (9.1%) experienced conversion to open surgery, and 15 (68.2%) also developed SR. The probability of LR-free survival at 36 months was 96% (95% CI, 94%-98%). According to the Cox proportional hazards regression model, the hazard ratio of LR was estimated to be 4.2 (95% CI, 2.9-6.2) times higher among patients with a positive circumferential radial margin than among those with a negative circumferential radial margin.
In this cohort study, transanal TME performed by experienced surgeons was associated with an incidence of LR and SR that is in line with the published literature on open and laparoscopic TME, suggesting that transanal TME may be an acceptable approach for management of rectal cancer.
提倡新型经肛门全直肠系膜切除术(TME)的人认为,该手术克服了传统治疗直肠癌方法的技术和肿瘤学挑战。然而,最近对于该手术的肿瘤学安全性存在争议。
评估经肛门 TME 与癌症局部复发(LR)的发生率以及在随访期间无 LR 发生的概率之间的关联。
设计、地点和参与者:这是一项多中心队列研究,使用了来自加拿大 8 个大容量直肠癌症学术机构的数据,纳入了在参与中心接受经肛门 TME 治疗的所有原发性直肠癌连续患者。该研究于 2014 年 1 月至 2018 年 12 月进行,数据分析于 2020 年 4 月 1 日至 2020 年 9 月 15 日进行。
经肛门 TME。
LR 的发生率作为切除质量的直接衡量指标进行报告。估计了 36 个月时无 LR 和无系统复发(SR)生存的累积概率。局部复发和 SR 的定义分别为在切除原发性肿瘤后,在盆腔内或盆腔外通过监视发现的 1 个或多个新病变的放射学或内镜证据。
在纳入分析的 608 例患者中,423 例(69.6%)为男性;中位年龄为 63 岁(四分位距 [IQR],54-70 岁)。中位随访 27 个月(IQR,18-38 个月)后,22 例(3.6%)患者发生局部复发。LR 的中位时间为 13 个月(IQR,9-19 个月)。22 例局部复发患者中,16 例(72.7%)为男性,14 例(63.6%)接受了新辅助放化疗,12 例(54.5%)为 AJCC 分期 III 期疾病。在局部复发患者中,16 例(72.7%)有阴性的环周切缘,20 例(90.9%)有阴性的远端切缘,2 例(9.1%)需要转为开放手术,15 例(68.2%)还发生了 SR。36 个月时无 LR 生存的概率为 96%(95%CI,94%-98%)。根据 Cox 比例风险回归模型,与阴性环周切缘相比,阳性环周切缘患者的 LR 风险比估计为 4.2(95%CI,2.9-6.2)倍。
在这项队列研究中,经验丰富的外科医生实施的经肛门 TME 与 LR 和 SR 的发生率与开放和腹腔镜 TME 的文献报道一致,这表明经肛门 TME 可能是一种可接受的直肠癌治疗方法。